Clinical trials: Exudative Macular Degeneration
Exudative Macular Degeneration, Retinal Hemorrhage
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
This study will recruit patients who have recently had a submacular haemorrhage (bleed under the part of the retina responsible for detailed vision), as a complication of wet age-related macular degeneration (wet AMD).
- Trial name
- TAPAS (NCT01835067)
- Testing
- Ranibizumab, C3F8 Gas, tPA
- Where
- 5 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- King's College Hospital NHS Trust
Macular Degeneration Exudative Eye Left, Macular Degeneration Exudative Eye Right
OCTA (Optical Coherence Angiography Tomography) Versus Structural OCT(Optical Coherence Tomography) in Neovascular AMD (Age Macular Degeneration)
The objective is to find if there is a relationship between the Fractal Dimension, the gap, vascular density (VD), the surface, the span ratio and the status of the choroidal neovessels to adjust the interval between 2…
- Trial name
- QUAOBARE (NCT03939195)
- Testing
- Follow-up
- Where
- 3 sites in France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Exudative Age-related Macular Degeneration
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
- Trial name
- NCT04138420
- Testing
- Bevacizumab Injection
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Federico II University
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab.
- Trial name
- CyPov (NCT02976194)
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Pusan National University Hospital
Exudative Age-related Macular Degeneration
Intravitreal Aflibercept for Submacular Hemorrhage
The prognosis of exudative age-related macular degeneration (AMD) accompanied by submacular hemorrhage is generally poor. A recently developed anti-VEGF agent eyeliaTM is also a useful treatment option for exudative AMD.
- Trial name
- NCT03169660
- Testing
- Vascular endothelial growth factor trap-eye
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Kim's Eye Hospital
Exudative Age-related Macular Degeneration
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
The aim of this study is to evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03744806
- Testing
- Bevacizumab Injection
- Volunteers
- 48 people
- Sponsor
- Medical University of Lublin
Exudative Macular Degeneration
Pilot Study of X-82 in Patients With Wet AMD
The objective of this study is to evaluate the safety and preliminary biologic activity/efficacy of X-82 in patients with wet Age-related Macular Degeneration (AMD).
- Trial name
- NCT01674569
- Testing
- X-82 oral, ranibizumab (Lucentis)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tyrogenex
Exudative Macular Degeneration
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.
- Trial name
- NCT01617148
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rishi Singh
Exudative Age-related Macular Degeneration
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
The purpose of this study is to test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative…
- Trial name
- PBAMD2 (NCT01213082)
- Testing
- 24GyE proton and Anti-VEGF, 16GyE and anti-VEGF
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Davis
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Non-exudative Age-related Macular Degeneration
Non-exudative Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in developed countries and is often discussed in terms of the "dry" and the "wet" forms.
- Trial name
- NEAMD (NCT01712841)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Exudative Age Related Macular Degeneration
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD…
- Trial name
- NCT02732899
- Testing
- Sirolimus, EYLEA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Macular Degeneration Exudative Eye Bilateral
The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients
This pathology, DMLA, whose evolution is chronic, requires regular follow-up and care (IVTs) over a long period (several months or even years).
- Trial name
- NCT03214484
- Testing
- By comparing the evolution of the visual acuity curves., By comparing the evolution of the curves.
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hospital St. Joseph, Marseille, France
Exudative Age Related Macular Degeneration
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patients receiving intravitreal…
- Trial name
- NCT01819415
- Testing
- Anti-VEGF plus AREDS-2, Anti-VEGF plus AREDS-1
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
- Trial name
- VAULT (NCT01950741)
- Testing
- aflibercept
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Pusan National University Hospital
Exudative Age-Related Macular Degeneration
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
The purpose of this study is to evaluate the fact that 20 milligrams per day of oral Zeaxanthin as a supplement to patients with Choroidal neovascularization (CNV) and exudative age related macular degeneration (ARMD) undergoing…
- Trial name
- ARMD (NCT01527435)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Retina Center of St. Louis County, PC
Exudative Macular Degeneration
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during…
- Trial name
- NCT02287298
- Testing
- TRIPLE COMBINATION THERAPY
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- The Retina Center of St. Louis County, PC